Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Baby girl due soon will be minus breast cancer causing gene

A baby girl about to be born in Britain will be the first to have been screened for a breast cancer causing gene.

22 Dec 2008

Surgeons perform first simultaneous double-lung, kidney transplant in Illinois, Wisconsin

Eric McCabe of Wausau, Wis., had no earth-shaking plans for the future as he began his recovery from the rare double-lung and kidney transplant surgery he had at Loyola University Medical Center in Maywood, Ill.

17 Dec 2008

Evolutionary roots of ancient bacteria may open new line of attack on cystic fibrosis

The redox-active pigments responsible for the blue-green stain of the mucus that clogs the lungs of children and adults with cystic fibrosis (CF) are primarily signaling molecules that allow large clusters of the opportunistic infection agent, Pseudomonas aeruginosa, to organize themselves into structured communities.

16 Dec 2008

Carrier screening for spinal muscular atrophy should be offered to all couples

Carrier screening for spinal muscular atrophy (SMA) - a serious genetic disease affecting approximately 1 in 10,000 infants that causes progressive muscle weakness and death - should be made available to all families, according to a new practice guideline issued by the American College of Medical Genetics (ACMG).

10 Dec 2008

Intervention in infants with cystic fibrosis key to slowing progression

Early detection of lung disease in cystic fibrosis (CF), combined with aggressive treatment in infants, may be the key to controlling the progression of the disease, according to a recent study.

5 Dec 2008

Six bad bugs increasingly escaping effects of antibiotics

Infectious disease experts warn that new drugs are urgently needed to treat six drug-resistant bacteria that cause most hospital infections and increasingly escape the effects of antibiotics.

1 Dec 2008

Altus Pharmaceuticals reaffirms plan to submit NDA for Trizytek

Altus Pharmaceuticals Inc. announced today that it is reaffirming its plan to submit a new drug application (NDA) for Trizytek TM (liprotamase) in the first-half of 2009.

18 Nov 2008

Researchers describe how cells recycle protein waste

Garbage collectors are important for removing trash; without them waste accumulates and can quickly become a health hazard.

11 Nov 2008

Australian-led global initiative to improve diagnosis of genetic disorders

An Australian-led global initiative to improve the diagnosis of genetic disorders and reduce errors in the reporting of genetic variations has been published today in the prestigious scientific journal Science.

7 Nov 2008

Universal test for genetic diseases in unborn children in the pipeline

A team of British scientists have developed a ground-breaking new test to screen for genetic diseases in unborn children.

27 Oct 2008

Simple gene-based blood test, quicker, more accurate evaluation for cystic fibrosis

Researchers at National Jewish Health have identified a simple gene-based blood test that more accurately and quickly measures cystic fibrosis patients' response to therapy than current tests.

26 Oct 2008

Kamada reports positive data with inhaled Alpha-1 Antitrypsin in cystic fibrosis

Kamada has announced today positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation.

12 Oct 2008

Children with cystic fibrosis not well covered by guidelines for vitamin D needs

Existing recommendations for treating vitamin D deficiency in children with cystic fibrosis (CF) are too low to cover the serious need, leaving most at high risk for bone loss and rickets, according to researchers at Johns Hopkins Children's Center.

12 Oct 2008

New pig model of cystic fibrosis provides better understanding of human disease

For the first time, researchers have developed a genetically altered animal model for cystic fibrosis (CF) that closely matches the characteristics of the disease in humans. By studying the complex and multi-organ disease process in the pig model, researchers can now better understand how the complications of CF develop, an advancement that may lead to new avenues for research in prevention and treatment.

25 Sep 2008

Protein opens hope of treatment for cystic fibrosis patients

Scientists have finally identified a direct role for the missing protein that leaves cystic fibrosis patients open to attack from lung-damaging bacteria, the main reason most of them die before their 35th birthday, scientists heard today (Thursday 11 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.

10 Sep 2008

New drug hope for cystic fibrosis patients

A science conference in the UK has heard some good news which offers hope to cystic fibrosis (CF) patients worldwide.

10 Sep 2008

New drug hope for cystic fibrosis patients

A new drug therapy may represent a tremendous step forward in the treatment of some 70,000 cystic fibrosis (CF) patients worldwide, Dr David Sheppard from the University of Bristol told an audience at the BA Festival of Science in Liverpool today [9 September].

9 Sep 2008

Rattlesnake-type poisons used by superbug bacteria to beat our defences

Colonies of hospital superbugs can make poisons similar to those found in rattlesnake venom to attack our bodies' natural defences, scientists heard today (Monday 8 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.

7 Sep 2008

Second phase 3 trial of Bronchitol in cystic fibrosis sufferers begins

Pharmaceutical company Pharmaxis today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

4 Sep 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008